Skip to main content

Advertisement

Table 2 Sensitivity, specificity, 95% confidence intervals and likelihood ratios

From: PTPN22polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease

  Sensitivity Specificity Likelihood ratio
  % 95% CI % 95% CI  
PTPN22 CT+TT 39.3 29.6–49.7 80.3 75.9–84.1 2.0
Anti-CCP Abs 37.1 27.5–47.5 98.6 96.9–99.5 26.2
IgG-RF 16.9 8.9–28.1 95.8 92.6–97.8 4.0
IgA-RF 42.4 30.3–55.2 94.9 91.5–97.2 8.3
IgM-RF 22.0 12.8–33.9 94.1 90.5–96.6 3.7
SE (B1*0404 or 0401) 55.6 45.2–65.6 61.8 54.4–68.9 1.5
SE + PTPN22 CT+TT 24.1 16.0–34.0 92.9 88.3–96.1 3.4
Anti-CCP Abs + PTPN22 CT+TT 22.1 14.3–31.8 100.0 - -
  1. Sensitivity, specificity, 95% confidence intervals (CIs) and likelihood ratios were determined for the presence of the PTPN22 1858T variant (CT+TT), anti-cyclic citrullinated peptide antibodies (anti-CCP Abs), rheumatoid factors IgM-RF, IgG-RF and IgA-RF, and carriage of human leukocyte antigen shared epitope (HLA-SE) in pre-patients and matched controls.